Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities (Q90263373)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31551657%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

title

Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31551657%20AND%20SRC:MED&resulttype=core&format=json

esophageal squamous cell carcinoma

12 April 2020

main subject

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31551657%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31551657%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31551657%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Hui Luo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31551657%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

publication date

29 July 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31551657%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

published in

OncoTargets and Therapy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31551657%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31551657%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

page(s)

6023-6032

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31551657%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 3.0 Unported

12 April 2020

start time

1 July 2019

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

1 reference

12 December 2020

Targeted therapies for esophageal cancer

1 reference

12 December 2020

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

1 reference

12 December 2020

Microsatellite instability and clinicopathological features in esophageal squamous cell cancer.

1 reference

12 December 2020

PD-1 and its ligands in tolerance and immunity

1 reference

12 December 2020

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

1 reference

12 December 2020

Paclitaxel and immune system

1 reference

12 December 2020

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

12 December 2020

Microsatellite instability in colorectal cancer

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

1 reference

12 December 2020

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

12 December 2020

The blockade of immune checkpoints in cancer immunotherapy

1 reference

12 December 2020

Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST

1 reference

12 December 2020

Epidemiologic differences in esophageal cancer between Asian and Western populations

1 reference

12 December 2020

Tumor Immunotherapy Directed at PD-1

1 reference

12 December 2020

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

12 December 2020

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

12 December 2020

Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients

1 reference

12 December 2020

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

1 reference

12 December 2020

Effects of anticancer agents on cell viability, proliferative activity and cytokine production of peripheral blood mononuclear cells

1 reference

12 December 2020

New and emerging combination therapies for esophageal cancer

1 reference

12 December 2020

Signatures of mutational processes in human cancer

1 reference

12 December 2020

PD-1 as a potential target in cancer therapy

1 reference

12 December 2020

The effect of radiation on the immune response to cancers

1 reference

12 December 2020

Current management of esophageal cancer

1 reference

12 December 2020

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.

1 reference

12 December 2020

Genetic basis for clinical response to CTLA-4 blockade in melanoma

1 reference

12 December 2020

Molecular and genetic properties of tumors associated with local immune cytolytic activity

1 reference

12 December 2020

PD-1 Restrains Radiotherapy-Induced Abscopal Effect.

1 reference

12 December 2020

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

12 December 2020

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

1 reference

12 December 2020

Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma

1 reference

12 December 2020

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

1 reference

12 December 2020

Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries

1 reference

12 December 2020

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

1 reference

12 December 2020

Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations

1 reference

12 December 2020

Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study

1 reference

12 December 2020

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

1 reference

12 December 2020

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

1 reference

12 December 2020

A liquid biopsy for cancer immunotherapy

1 reference

12 December 2020

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab

1 reference

12 December 2020

Radiotherapy combination opportunities leveraging immunity for the next oncology practice

1 reference

12 December 2020

A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma

1 reference

12 December 2020

Elements of cancer immunity and the cancer-immune set point

1 reference

12 December 2020

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

1 reference

12 December 2020

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

1 reference

12 December 2020

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

1 reference

12 December 2020

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

1 reference

12 December 2020

Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.

1 reference

12 December 2020

Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial

1 reference

12 December 2020

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

1 reference

12 December 2020

Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma

1 reference

12 December 2020

Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients

1 reference

12 December 2020

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

1 reference

12 December 2020

Safety, activity and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma

1 reference

12 December 2020

Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis.

1 reference

12 December 2020

Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study

1 reference

12 December 2020

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition

1 reference

12 December 2020

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

1 reference

12 December 2020

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

1 reference

12 December 2020

Hyperprogressive disease: recognizing a novel pattern to improve patient management

1 reference

12 December 2020

Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic

1 reference

12 December 2020

Anti-PD1 'SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement.

1 reference

12 December 2020

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

1 reference

12 December 2020

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study

1 reference

12 December 2020

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

1 reference

12 December 2020

Immune checkpoint inhibitors in esophagogastric adenocarcinoma: do the results justify the hype?

1 reference

12 December 2020

Liquid biopsy for lung cancer immunotherapy.

1 reference

12 December 2020

Identifiers

DOI

10.2147/OTT.S214579

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31551657%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31551657%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

PubMed publication ID

31551657

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31551657%20AND%20SRC:MED&resulttype=core&format=json